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Abstract 
Recurrent acute sickle cell painful crises are the hallmark of sickle cell anemia. These 
events may be mild, moderate or severe in nature and  often require treatment at home, 
in acute care facilities as outpatients, and in the hospital with oral and/or parenteral 
opioids. The type, dose, route & frequency of administration of opioids, as well as the 
length of hospital stay (LOS), are not well known for adults with sickle cell anemia (SS). 
We analyzed these aspects in the 299 patients enrolled in the Multicenter Study of 
Hydroxyurea (MSH) in SS.  For these patients there were 16818 home diaries, 2249 
acute care contacts, and 2209 hospitalizations. At home analgesics were used on 40% 
of diary days and 80% of 2-week follow up periods, with oxycodone and codeine the 
most frequently used. Responders to hydroxyurea (HU) used analgesics on fewer days.  
During hospitalization 96% were treated with parenteral opioids, with meperidine the 
most frequently used; oxycodone was the most commonly used oral medication. The 
average LOS for responders to HU was about two days less than for other groups and 
their cumulative time hospitalized during the trial was significantly less than for 
nonresponders or placebo groups (p<0.022).  They also had the lowest doses of 
parenteral opioids during acute care crises (p=.015). 
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Introduction 
Sickle cell anemia (SS) is a quadrumvirate of pain syndromes, anemia and its 
sequelae, organ failure including infection, and co-morbid disorders.1-4   Pain, however, 
is its predominant feature and the major complaint of patients throughout their life.5-9  
Sickle cell pain can be of mild, moderate, or severe intensity and is usually sharp or 
throbbing in nature, but can also be stabbing, deep, achy, lacerating, or shooting in 
quality.5-9  Pain that is of mild or moderate intensity is usually treated at home with oral 
or topical analgesics plus certain non-pharmacological modalities.5-9  Severe pain, 
however, often requires emergency room and/or hospital in-patient treatment with 
parenteral opioids. There are only rare multicenter randomized controlled trials that 
compare the effect of drug treatment on the length of hospital stay for painful crises in 
adult patients with SS.10,11  Anecdotes and  reports from single institutions indicate the 
duration of hospitalization for an uncomplicated painful crisis in adult patients varies 
between 6 and 10 days.12-15 
Nonopioid analgesics, adjuvants, topicals and oral opioids are often used during 
hospitalization in addition to parenteral opioids. The amount of opioids required by 
patients during hospitalization in order to achieve pain relief is often so high that it 
concerns some providers who are not familiar with sickle cell disease and, 
consequently, tend to under-treat patients with sickle cell pain.  Some providers may 
refuse to prescribe high doses of opioids during hospitalization and often accuse 
patients of being malingerers, drug- seeking or even drug addicts. 
To the best of our knowledge there are no multicenter randomized controlled 
trials in the literature that describe the amount of opioids consumed by adult patients 
with SS at home and during acute painful episodes that are treated as outpatients or 
during hospitalization. Reports from single institutions described the utilization of 
NSAIDs alone or in combination with certain opioids in a relatively small number of 
hospitalized adult patients.16,17  Another small study compared the utilization of 
parenteral butarphenol with morphine in adult patients in the emergency room.18  Other 
reports addressed the factors that affect the quality of pain management in sickle cell 
disease (SCD).19-21  The Multicenter Study of Hydroxyurea (MSH) in SS22 gave us an 
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opportunity to report on this aspect of sickle cell disease. Although the original MSH 
study showed that hydroxyurea decreased the frequency of painful crises that required 
hospitalization, it did not address the duration of the painful crises or the amounts of 
opioids used to control crisis pain during hospitalization, and it did not differentiate 
between responders to HU and nonresponders. To that end, the goals of this paper are 
to (1) determine the hospital length of stay (LOS) of adult patients with SS enrolled in 
MSH 2) summarize the type and amount of opioids and other analgesics used by 
patients at home and during acute painful crises, and (3) compare the LOS and opioid 
utilization between the placebo and hydroxyurea treatment groups, and between 
treatment responders and nonresponders within the hydroxyurea group. 
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Methods 
Patient characteristics 
The methods of the MSH in SS have been described in detail elsewhere.22 
Briefly, MSH participants had to be at least 18 years old, with a diagnosis of SS, and at 
least 3 acute painful crises in the year prior to enrollment. A total of 299 patients were 
enrolled from 21 sites (20 in the United States and 1 in Canada).  There were no 
significant differences between the hydroxyurea (HU) and placebo groups in terms of 
sex, race, age, or blood counts at baseline. The sample included roughly equal 
numbers of male (49%) and female (51%) patients, with an average age of 30 years 
(range 18-59) at study entry.   
Measures 
Data on opioid use came from three sources: a “Patient Diary” form covering two-
week periods, completed daily at home by patients, and returned to clinical sites at 
follow-up visits; a “Follow-Up Visit” form, completed by physicians at regular follow-up 
visits every two weeks; and a “Medical Contact” form, completed by physicians 
whenever a patient presented for any medical contact other than the regular follow-up 
visits.  
On the Patient Diary, patients indicated daily severity of pain and use of any 
analgesic (but not the specific analgesic or dosage). The patient diaries were used to 
determine overall frequency of at-home analgesic use.  Analgesic frequency was 
defined as the proportion of all days on which patients reported using analgesics.   
 
On the Follow-Up Visit form, physicians indicated use of any oral or transdermal 
opioid since the last visit and the specific opioids used, the total dosage (in mg) since 
the previous visit, and the number of days that the analgesic was taken.  Physicians 
could indicate one or more of six opioids directly listed on the form (meperidine, 
oxycodone, morphine, hydromorphone, codeine, and the fentanyl patch) or write in 
others.  The four most common write-ins were coded for this analysis (methadone, 
propoxyphene, levorphanol, and hydrocodone).  The Follow-Up Visit form was used to 
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examine frequency of at-home analgesic use (as the proportion of all biweekly periods 
in which patients reported analgesic use), multiple analgesic use, and frequencies and 
dosages for specific analgesics.     
On the Medical Contact forms, physicians indicated the location of each contact 
(in-patient, emergency facility, MSH clinic, non-MSH clinic, doctor’s office, or ‘other’).  
More than one choice could be marked if a single contact involved a visit to more than 
one type of facility.  Physicians indicated use of specific analgesics from three 
categories: oral or transdermal opioids (meperidine, oxycodone, morphine, 
hydromorphone, codeine, and the fentanyl patch), parenteral opioids (meperidine, 
morphine, and hydromorphone), and non-steroidal anti-inflammatory agents (NSAIDs) 
(Ketorolac).  The most common write-in oral opioids (hydrocodone and methadone) and 
parenteral opioids (nalbuphine and butorphanol) were also coded.  Use of NSAIDs was 
uncommon and no write-ins were coded.  Physicians indicated the total dose (in mg) for 
each medication and the number of days that medication was used.   
Painful crises 
Analysis of hospital length of stay (LOS) and of analgesic use during acute care 
and in-patient contacts was restricted to contacts defined as sickle cell-related acute 
painful crises under the criteria of the MSH clinical trial.  In the trial, crises were defined 
as visits to a medical facility that lasted more than four hours for acute sickling-related 
pain, which was treated with a parenterally administered opioid (except for a few 
facilities in which only orally administered opioids were used).22 Analyses were 
restricted to painful crises in order to exclude medical contacts that might not be related 
specifically to sickle cell pain or to other complications of the disease or comorbid 
disorders. 
Painful crises were divided into two categories: those involving in-patient 
hospitalization and those involving only acute care facilities.  If a crisis included in-
patient hospitalization, regardless of contact with another type of facility, it was coded as 
in-patient.  If the crisis involved only an outpatient acute care facility (ER, MSH clinic, 
non-MSH clinic, or doctor’s office), it was coded as acute care.  In all subsequent 
analyses, these categories were examined separately.  The Medical Contact Form 
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provided data on the overall frequency of analgesic use, multiple analgesic use, and the 
frequencies and dosages for specific analgesics, during painful crises.   
Treatment group assignment and hydroxyurea response  
Assignment to the HU or placebo group at study entry was a key predictor of 
interest for analgesic usage. HU recipients were also divided into responder and 
nonresponder groups, based on fetal hemoglobin (HbF) levels at baseline and at 
approximately 18 months after initiation of treatment.  A responder was defined as any 
HU recipient whose baseline percentage of HbF was < 15%, but whose follow-up level 
was >= 15%.  This definition was based on previous research suggesting that 15% fetal 
hemoglobin is a level expected to produce clinical benefits 23,24, and this level is defined 
by NHLBI treatment guidelines as a desired treatment outcome.25   Thus, an increase of 
this magnitude in HbF could reasonably be expected to produce clinically salutary 
benefits.   
Statistical Methods 
Types and dosages of at-home, acute care, and in-hospital analgesic usage 
were explored descriptively.  Frequencies of use for each analgesic were expressed in 
three ways: as (1) percentages of all at-home periods, acute care crises, and in-patient 
crises, (2) percentages of only those periods that involved analgesic use (for at-home 
use only), and (3) percentages of the total number of analgesics used across all at-
home periods, acute care, and  in-patient crises.   
 
Equianalgesic doses were computed for each opioid, using standard formulas to 
convert doses into morphine equivalents.6   For painful crises, total dosages for each 
opioid were converted to morphine equivalents and summed to get a single total 
dosage.  Average daily doses were calculated by dividing the total dose by the number 
of days that the crisis lasted.  When the crisis duration was less than one day, the 
number of days was set to one.  
For at-home use, total dosages reported for each opioid on the Follow-up Visit 
form were converted to equianalgesic doses and summed to get an overall total.  To 
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obtain daily averages, total doses were divided by the number of days of analgesic use 
reported on the Patient Diary corresponding to that Follow-Up Visit form.  Total days of 
use were obtained from the Pain Diaries rather than the Follow-up Visit forms because 
data for days of use were much more complete in the Diaries.  Patient diaries and 
Follow-Up Visit forms were matched using codes for visit number that appeared in the 
data file for each form. 
A check on data distribution indicated extreme non-normality (high skewness and 
kurtosis) for variables related to equianalgesic dosing.  All equianalgesic dosing 
variables were transformed using the natural logarithm to normalize data distributions.  
The log-transformed values were used for group comparisons in the modeling described 
below; least squares means (LSM) estimates from the models were exponentiated to 
convert LSM estimates back into units of mg morphine equivalent.  The same procedure 
was used for data on the number and duration of painful crises. 
The effects of treatment group and HU response on analgesic usage were 
examined through between-group comparisons of (a) the proportion of all diary days 
with analgesic use, (b) the occurrence of any analgesic use during at-home follow-ups, 
acute care crises, and in-patient crises, (c) the total number of different analgesics 
reported for each at-home follow-up, acute care, and in-patient painful crisis, (d) the 
total (two-week) and average (daily) equianalgesic doses used at home, (e) the daily 
equianalgesic doses used during acute care and in-patient painful crises; (f) cumulative 
dosing across at-home follow-ups and painful crises for each patient; and (g) the 
frequency, average duration, and cumulative duration of acute care and in-patient 
painful crises.   
Group differences in the proportion of diary days with analgesic use were tested 
with linear regression models.  Differences in analgesic use at home and use of 
parenteral and oral opioids and NSAIDs during painful crises were tested with Rao-
Scott adjusted chi-square analyses (to control for multiple observations of each patient).  
Total analgesics used during each at-home follow-up and painful crisis were compared 
with Wilcoxon rank-sum tests with adjustment for clustering (to control for multiple 
observations of each patient).  Differences in average and cumulative equianalgesic 
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dosing at home and during painful crises, and average and cumulative duration of 
painful crises, were tested with repeated-measures linear mixed models.  Finally, 
frequency of acute care and in-patient painful crises were modeled with zero-inflated 
Poisson regression, due to large proportions of zeros and non-normality of the data.  
Results were considered statistically significant if the associated p-value was ≤.05, and 
‘marginally significant’ if .05<p≤ .10.   
In light of the number of comparisons tested, the suggested thresholds for 
statistical significance (p <.05) and marginal significance (0.05 < p <0.10) are intended 
only as a rough non-conservative guideline for all the post hoc analyses performed in 
this manuscript. 
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Results 
Type and frequency of analgesic use at home  
Overall frequency.  Patients’ average length of time in the MSH trial was 790 
days (2.16 years).  Based on the Patient Diaries, the mean and median percent of days 
with analgesic use were 39.9% and 35.0%, respectively, with a range from almost 0% to 
over 99% of all days.  Of 16818 biweekly follow-up visits, oral opioid use was reported 
in 59.9% (this does not imply analgesic use on all days of each two-week follow-up 
period).   
Frequency of individual analgesics.  Table 1 lists the frequency of use for each 
opioid as a percentage of (a) all biweekly follow-up visits (n=16818); (b) only those visits 
for which opioid use was reported (n=10071); and (c) the total number of opioids 
reported (the sum of separate opioids from follow-up form; n=11302).  Oxycodone and 
codeine were used most often, at 23% and 18% of all two-week follow-ups, 
respectively. Together they accounted for 61.7% of all analgesics used and were at 
least three times as frequent as the next most common opioids (meperidine and 
hydromorphone).  Figure 1 displays frequency of use and mean dose (before 
equianalgesic transformation) for each oral opioid at home.  
Equianalgesic dosing.  The mean total dose during periods when analgesics 
were used was 219.6 (SD=480.69) mg morphine equivalent; the median was 112.5 mg 
morphine equivalent.  For those days on which analgesics were used, the mean and 
median daily doses were 25.1 (SD=40.79) and 15 mg morphine equivalent, 
respectively.  Because analgesics were typically not used every day, the average two-
week total is not simply a multiple of the average daily dose. 
Relationship of treatment assignment and treatment response to at-home analgesic use 
Frequency of at-home use.  Based on Patient Diaries, placebo patients used 
analgesics on 42.0% of all days, compared to 38.0% for hydroxyurea patients; however, 
this difference was not statistically significant.  The difference in use of any analgesic 
during biweekly periods was also nonsignificant (58.8% for HU and 59.7% for placebo).  
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There was no significant difference between treatment groups in the use of multiple 
analgesics.  
HU responders, however, used analgesics on significantly (p=.005) fewer days 
(22.6%) than either nonresponders (42.2%) or placebo patients (42.0%).  HU 
responders also used analgesics during significantly fewer two-week periods (40.8%) 
than either nonresponders (63.3%) or placebo patients (59.7%), p=.006.  When 
compared for use of multiple medications, responders used fewer than either 
nonresponders or placebo patients (p<.0001). 
Equianalgesic dosing during at-home use.  Table 2 summarizes least squares 
means (LSM) estimates from the mixed models of daily and two-week at-home dosing.  
The HU and placebo groups did not significantly differ in average daily dosing at 11.3 
and 11.5 mg morphine equivalent, respectively, p=.89.  For two-week total doses, the 
HU and placebo groups again did not significantly differ (p=.60).    
For treatment response, average daily dosing for HU responders and 
nonresponders did not differ, at 11.1 and 11.4 mg morphine equivalent, respectively 
(p=.98).  For two-week total doses, the difference in mean values was again not 
statistically significant (p=.18).  However, the median value for two-week total dose is far 
lower for responders (45 mg) than nonresponders (135 mg), reflecting use by 
responders on significantly fewer days; variation in two-week totals was large (even 
after log transformation) and may have prevented the group difference from reaching 
significance.  
Type and frequency of analgesic use during acute care (outpatient) contacts  
Overall frequency.  There were 2249 acute care contacts, not leading to in-
patient hospitalization, that were defined as painful crises.  Of these, 95.5% reported 
treatment with parenteral opioids, 10.9% with oral opioids, and 9.2% with NSAIDs (the 
three categories sum to more than the 100% because of multiple analgesic use by 
some patients).   
Frequency of individual analgesics.  Table 3 shows frequency of use of 
analgesics during painful crises.  The most frequently used parenteral opioid was 
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meperidine, at 69.3% of contacts; hydromorphone was second, at only 14.3% of 
contacts.  The most common oral opioid was oxycodone, at 3.9% of contacts.  Figures 2 
shows the percent of all acute care crises during which each parenteral opioid was 
used.    
Dosing.  During acute care crises with analgesics use, mean and median daily 
doses of parenteral opioids were 33.9 (SD=33.93) and 26 mg morphine equivalent, 
respectively.  For crises with oral opioid use, mean and median doses were 29.8 mg 
(SD=45.23) and 15 mg morphine equivalent, respectively.     
Relationship of treatment assignment/response to acute care analgesic use. 
Frequency of acute care use.  Placebo and HU patients did not differ in use of 
parenteral opioids (p=.90), oral opioids (p=.60) or NSAIDs (p=.53).  
HU responders were more likely than nonresponders or placebo patients to use 
NSAIDs during outpatient acute care contacts (43.2% of contacts versus 6.6% and 
10.0%, respectively), p<.0001; however, use of oral and parenteral opioids did not differ.  
There were no differences in the total number of different analgesics used during 
acute care painful crises, either between treatment groups (p=.90) or between treatment 
response groups (p=.77).   
Equianalgesic dosing during acute care painful crises.  Results of mixed 
modeling for daily dosing are reported in Table 4. LSM estimates for treatment groups 
did not significantly differ for either oral dosing (p=.18) or parenteral dosing (p=.93).  
Response groups also did not significantly differ in either parenteral dosing (p=.41) or 
oral dosing (p=.60). 
Type and frequency of analgesic use during in-patient painful crises  
Overall frequency.  There were 2209 painful crises involving in-patient 
hospitalizations.  Of these contacts, 96.4% reported use of parenteral opioids, 47.7% 
oral opioids, and 11.3% NSAIDs.   
Frequency of individual analgesics.  Table 3 shows frequency of use for specific 
analgesics during in-patient crises.  The most frequently used parenteral opioid was 
meperidine, at 75.3% of crises; morphine was second at 19.0%.  The most common 
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oral opioid was oxycodone (at 19.6% of in-patient crises), with all others less than half 
as frequent.  Figures 2 shows use of each parenteral opioids  as a percent of all in-
patient crises.    
Medical inpatient contact dosing.  The mean and median daily doses of 
parenteral opioids (when used) were 95.9 mg (SD=203.4) and 67 mg morphine 
equivalent, respectively.  For crises involving use of oral opioids, mean and median 
doses were 75.2 mg (SD=182.93) and 40 mg morphine equivalent, respectively.  
Relationship of treatment assignment /treatment response to in-patient analgesic use. 
Frequency of hospital contact use.  HU and placebo patients did not significantly 
differ in use of parenteral opioids (p=.71), oral opioids (p=.57) or NSAIDs (p=.26).  
Similarly, responders and nonresponders did not significantly differ in use of parenteral 
opioids (p=.73), oral opioids (p=.64), or NSAIDs (p=.48).  Finally, neither the treatment 
groups nor the response groups differed in total analgesics used during in-patient 
contacts, p=.75 and p=.84, respectively.   
Equianalgesic dosing during in-patient painful crises.  Mixed model results for 
daily parenteral and oral dosing, by treatment and response groups, are reported in 
Table 4.  LSM estimates of dosing indicate nonsignificant differences between treatment 
groups for both parenteral (p=.80) and oral (p=.96) use.  There were also no significant 
differences   among HU responder, nonresponder, and placebo patients in estimates of 
parenteral dosing (p=.71) or oral dosing (p=.43).  Notably, median values for parenteral 
and oral dosing, and to a lesser extent mean estimates for parenteral and oral dosing, 
are higher for responders than nonresponders.  Responders were both fewer in number 
and had significantly fewer in-patient crises (see below) than nonresponders. 
Differences in number and duration of acute care and in-patient painful crises. 
Previously, it has been shown that HU patients in MSH had a significantly lower 
rate of painful crises than did placebo patients22.  We examined differences separately 
for acute care and in-patient painful crises, and between HU responders and 
nonresponders as well as treatment groups.  Table 5 shows mean and median values 
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for the numbers of acute care and in-patient painful crises by treatment group and 
response group, and the mean and median duration of in-patient painful crises. 
Number of in-patient and acute care crises.  All models controlled for duration of 
patients’ participation in the study.  There was a significant difference between 
hydroxyurea and placebo groups in the number of in-patient painful crises (p=.0015), 
with fewer crises for hydroxyurea patients than for placebo patients.  When divided into 
HU responders and nonresponders, differences were again significant (p<.0001), with 
the HU responders having significantly fewer in-patient crises than the nonresponders.  
Regression modeling also showed a significant difference between treatment groups in 
the number of acute care crises (p<.0001) and between response groups as well 
(p<.0001), with fewer crises for hydroxyurea patients compared placebo patients and for 
responders compared to nonresponders.    
Average duration of in-patient and acute care crises.  When crises did occur, 
there were no significant group differences in the average duration of those crises.  For 
in-patient crises, average duration did not significantly differ for either treatment groups 
(p=.74) or response groups (p=.45); for acute-care crises, average duration also did not 
differ between treatment (p=.76) or response (p=.96) groups.  However, as shown in 
Table 6, the average duration of in-patient crises was almost two days shorter for HU 
responders than for either non-responders or placebo patients.   
Cumulative duration of in-patient and acute care crises.  We also examined 
cumulative duration of in-patient painful crises and acute care painful crises.  For each 
patient, we calculated the total amount of time spent hospitalized and in acute care by 
separately summing the duration of all in-patient and acute-care crises for that patient.  
The cumulative values were then transformed using the natural logarithm to normalize 
the data. Mixed models were used to compare cumulative duration between treatment 
groups and between response groups. 
For treatment groups, there were no statistically significant differences in dosing 
or duration for in-patient care.  There were marginally significant differences for 
parenteral dosing during acute care (p=.10), with lower total doses for patients using 
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HU, and for the cumulative duration of acute care crises (p=.095), with less cumulative 
time for HU patients. 
For response group comparisons, multiple significant differences emerged.  
Table 6 shows mean and median values for cumulative dosing and cumulative duration, 
by response groups.  HU responders spent less cumulative time hospitalized (p=.022) 
and less cumulative time in acute care (p=.015); they also had the lowest doses of 
parenteral opioids during acute care crises (p=.015).  These differences emerged 
despite extreme variation in the cumulative dosing and duration variables (see SDs in 
Table 7); large numerical differences in other values (such as in-patient parenteral 
dosing) may not have been statistically significant (even after log transformation) due in 
part to the large SDs.  
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Discussion 
The insignia of sickle cell disease (SCD), in general, and sickle cell anemia (SS), in 
particular, is the recurrent acute painful crisis that often requires admission to the 
hospital through the emergency department and treatment with relatively large amounts 
of opioids for a lengthy hospital stay that may last, in some patients, over one week. 6,26-
28
 The duration of the acute sickle cell painful crisis and its management has been a 
conundrum of confusion punctuated with assumptions, suspicions, stigmatization, faulty 
accusations, under-treatment, occasionally over- treatment, barriers to quality 
comprehensive care, and disparities. The acute sickle cell painful crisis is the most 
common cause of hospitalization of patients with SS. Besides the acute and severe 
pain, the crisis is often associated with other complications of the disease including, 
among other thing, infection, acute chest syndrome, hyperhemolysis, and sudden 
death.4,6,29-32 These serious complications associated with the painful crisis usually 
manifest themselves within 1-5 days after hospital admission when discharge from the 
hospital is imminent. The duration of the crisis and its management with opioids has 
been a subject of controversy for a long time. Most insurance carriers approve regular 
payments for the care of admitted patients with painful crises for 3 or 4 days unless a 
longer hospital stay is justified. Panepinto et al. 33 found that the overall average of the 
hospital length of stay in children with sickle cell painful crises was 4.4 days with older 
children having longer LOS. Ellison and Bouchner 34 found that the unadjusted mean ± 
SD of the LOS for the Medicaid children with SCD was 4.0 ±6.24 days compared to 3.0 
± 5.22 for patients with private insurance. These 3 to 4 days of hospital LOS is often 
applied to adult patients with SS pari passu. To that end patients may be discharged 
prematurely and about 16% of discharged patients are readmitted within one week after 
discharge and about 50% are readmitted within one month .35,36   Moreover, Davis et al. 
analyzed National Inpatient Sample trends from 1989-1993, and found on average an 
estimated 75,000 hospitalizations per year of SCD children and adults, with lengths of 
stay less than 5 days for children and over 7 days for adults.37 Limiting the LOS per 
diagnosis by Insurance carriers seems to encourage providers to discharge their 
patients prematurely- a practice that is invariably associated with hospital readmission 
within a short period after discharge 38 The MSH study gave us a great opportunity to fill 
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the gap of knowledge pertinent to the LOS and the amount of opioid and non-opioid 
analgesics consumed by patients with SS as outpatients and during hospitalization for 
acute painful crises. 
The MSH data showed that patients on HU are admitted less often to the hospital than 
patients on placebo. Moreover, when patients who responded to HU are admitted to the 
hospital for a painful crisis, the chances are that they will stay 2 days less than patients 
not taking or not responding to HU. The reduction in the frequency of hospital 
admissions and the shortened length of hospital stay amount to significant savings per 
admission per patient as was described previously.39 Using 2009 charges, savings 
amount to an estimated savings of about $27,000 per 7-day hospital admission per 
patient. 40 Thus, besides its beneficial effects on morbidity and mortality 41due to SS, HU 
has significant financial benefits. It is unfortunate that HU is underutilized 28 in the 
management of patients with SS in view of the potential savings to the institutions taking 
care of patients with SCD and to Medical insurance providers. 
The second important aspect of this study is that it provides important information about 
the amount of opioid and non-opioid analgesics used by patients as outpatients and 
during acute painful crises. At home patients with SS use opioid analgesics frequently 
with oxycodone and codeine being the most commonly opioids used followed by 
meperidine and hydromorphone. Patients reported in their diaries that they used opioids 
about 40% of the time and some used them almost daily. This is similar to the data 
reported in the PiSCES study. 8 The oxycodone used was the short-acting one, 
because at the time of the trial in 1992-1995, the controlled release opioids (MScontin 
and Oxycontin) were either not available or were not in common use. Patients who 
responded to HU showed three significant differences in comparison to nonresponders 
and placebo groups: 1) they used analgesics on fewer days at home; 2) they used 
analgesics during fewer of two-week follow-up periods; and 3) they used multiple 
medications less often than the other two groups. These findings suggest that HU 
seems to ameliorate the severity of painful episodes that occur at home. 
HU, however, did not affect the use of any analgesic category during acute painful 
episodes treated as outpatients in the emergency department, clinic, medical office or 
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day unit.  Responders to HU were more likely than nonresponders and placebo groups 
to use NSAIDs during these crises, but there was no difference in the use of parenteral 
or oral opioids.  Again this may suggest that the pain intensity in these crises seems to 
be slightly milder in responders in comparison to nonresponders.  
As was reported previously 22, HU decreased the frequency of painful crises by 
about 50%. The decrease in responders is even more impressive and amounts to about 
75% reduction in the number of painful crises that require hospital admission. Moreover, 
the hospital length of stay is about 2 days shorter than nonresponders or placebo 
groups.  The average daily amount of opioids used by the placebo group during 
hospitalization, however, is not significantly different from the responder and 
nonresponder groups. This suggests that the severity of painful crises during 
hospitalization seems to be the same during the initial days of the crisis in the placebo 
and HU groups. Responders may have been hospitalized only for the most severe 
crises while nonresponders were hospitalized more often and their hospitalizations may 
have included many milder crises. Since responders to HU are admitted to the hospital 
less frequently and their length of stay is about 2 days shorter per admission, the 
cumulative amount of opioids responders utilize over time is much smaller than that 
consumed by the placebo and nonresponder groups.  The advantages of this reduction 
are not only financial but include the reduction of side effects associated with long term 
use of opioids including, among other things, tolerance, dependence and hyperalgesia. 
Thus HU decreases the frequency of hospital admissions due to crises, shortens their 
duration, decreases the frequency of acute chest syndromes  and reduces the net 
amount of opioids utililized during hospitalization.  Moreover, should hydroxyurea be 
approved for use in children the medical and financial benefits would be substantial. 
Another aspect of this study that should be addressed pertains to the high utilization of 
meperidine during MSH. This was the drug of choice between the 1960’s and 1990’s 
and the preferred opioid by the majority of patients. One of the reasons is that the FDA 
approved meperidine for the treatment of severe pain in November 1942, whereas, 
morphine sulphate was approved in January 1984. The decline in the utilization of 
meperidine is due to the epileptogenic effect of normeperidine, its major metabolite. The 
use of meperidine for the treatment of sickle cell painful crisis continues to be 
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controversial.42-44 There is consensus at the present that meperidine should not be used 
in patients with history of seizure or in the presence of renal impairment. The reported 
incidence of seizures due to meperidine varies between 1 to 12 %. 45,46 The 
disadvantages for morphine are that its utilization in patients with SCD seems to be 
associated with acute chest syndrome 47-48 and that it induces kidney injury in the 
transgenic sickle cell mouse.49 The increase in acute chest syndrome could be 
incidental due to increased awareness among providers of the severity of pulmonary 
complications of SCD. Whether the advent of morphine sulphate has anything to do with 
this increase remains to be determined. 
 
In Conclusion this study shows that the beneficial effects of treating sickle cell anemia 
with hydroxyurea include shortening the duration of hospitalization due to acute painful 
episodes and reducing the net amount of opioid utilization during hospitalization in 
addition to its known effects of reducing the frequency of hospital admissions due to 
crises,22 reducing the frequency of acute chest syndrome,22 improving the quality of 
life50  and decreasing morbidity & mortality.41,51 
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Tables 
 
Table 1. 
Frequency of at-home opioid use 
Opioid Frequency     
(listed in order of 
frequency) 
% of all diaries 
(n=16818) 
% of diaries with 
any opioid usea 
(n=10071) 
Mean daily dose, 
mg (SD)b 
Median daily dose, 
mgb 
Any opioid 59.9 100.0 NA NA 
Oxycodone  23.2 39.1 15.5     (9.65) 12.3 
Codeine 18.3 31.0 79.8   (77.24) 60.0 
Meperidine  6.7 11.4 186.7 (190.70) 118.3 
Hydromorphone  6.6 11.2 7.1     (5.21) 4.4 
Hydrocodone  5.4 9.0 22.6   (18.98) 16.4 
Morphine 3.3 5.6 40.2   (25.57) 30.0 
Methadone 1.4 2.3 17.2   (10.34) 20.0 
Propoxyphene  0.9 1.6 163.6   (79.15) 133.3 
aTotals in this column sum to more than 100% due to multiple medication use at some visits. 
b
 mg=milligrams, SD=Standard deviation.  Values in these columns are the original dosage of each 
opioid, not the transformed equianalgesic dosages. 
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Table 2.   
Equianalgesic dosing (mg morphine equivalent), at-home periods with any analgesic use 
 
aMeans(standard error) Medians 
 Two-week total 
dose 
 
Average daily 
dose 
Two-week total 
dose  
 
Average daily 
dose  
Treatment group 
    
Hydroxyurea (n=152) 59.7 (1.11) 11.3 (1.08) 114.0 15.0 
Placebo (n=147) 64.4 (1.11) 11.5 (1.08) 112.5 15.0 
HU response group 
    
Responders (n=27) 43.4 (1.28) 11.1 (1.21) 45.0 13.2 
Nonresponders (n=116) 62.7 (1.12) 11.4 (1.09) 135.0 15.6 
aDerived from least squares means (LSM) estimates in mixed models of log-transformed data.  All values 
expressed as mg morphine equivalent. 
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Table 3. 
Frequency and dosage in mg of opioid and NSAID use during painful crises  
Analgesic % of all acute 
care contactsa 
(n=2249) 
Daily dose 
during acute 
care crises, 
mean (SD)b 
Daily dose 
during acute 
care crises, 
medianb 
% of all in-
patient contactsa 
(n=2209) 
Daily dose 
during in-patient 
crises, mean 
(SD)b 
Daily dose 
during in-patient 
crises, medianb 
Parenteral (any): 95.5        NA NA 96.4        NA NA 
  Meperidine  69.3 248.4 (145.70) 225 75.3 523.4 (382.40) 463 
  Hydromorphone  14.3   12.5 (9.26)   12 15.6   30.2 (65.26)   19 
  Morphine    8.9   18.8 (20.85)  14 19.0   53.3 (110.82)   30 
  Butorphanol   2.3     7.5 (4.81)    8   1.0   10.4 (12.45)     5 
  Nalbuphine    3.3   40.4 (14.84)  40   0.7   45.1 (23.3)   40 
Oral (any): 10.9        NA NA 47.7        NA NA 
  Oxycodone    3.9   14.1 (11.34)  10 19.6   28.2 (23.47)   25 
  Meperidine    2.5 248.7 (311.52) 175   8.6 415.4 (303.22) 371 
  Hydromorphone    2.2     8.3 (4.80)    8   8.0   27.6 (96.73)     8 
  Morphine   1.1   62.0 (59.36)  60   7.9 143.1 (158.15)   90 
  Codeine   1.2   69.7 (43.94)  60   7.7 113.3 (72.82)   90 
  Hydrocodone   0.3   14.9 (11.73)  10   1.7   57.6 (182.41)   14 
  Methadone   0.5   27.4 (9.68)  30   1.6   39.3 (41.26)   28 
aTotals for individual analgesics in a category sum to more than the category total due to multiple analgesic use at some contacts. 
bOriginal doses of each drug (prior to conversion into mg morphine equivalent) 
NA=Not applicable. 
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Table 4. 
Daily equianalgesic dosing during acute care (outpatient) painful crises 
 
aMeans (standard error) Medians 
 Average daily 
parenteral dose 
Average daily 
oral dose 
Median daily 
parenteral dose 
Median daily 
oral dose 
Treatment group 
    
Hydroxyurea (n=152) 22.8 (1.07) 19.1 (1.10) 39.0 15.0 
Placebo (n=147) 22.6 (1.06) 22.7 (1.09) 32.5 18.0 
HU response group 
    
Responders (n=27) 17.7 (1.23) 16.0 (2.23) 13.0 16.0 
Nonresponders (n=116) 23.5 (1.07) 20.2 (1.11) 39.0 16.0 
aDerived from least squares means (LSM) estimates in mixed models of log-transformed data.  All values expressed as mg morphine equivalent. 
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Table 5. 
Daily equianalgesic dosing, in-patient painful crises  
 
aMeans (standard error) Medians 
 Average daily 
parenteral dose 
Average daily 
oral dose 
Median daily 
parenteral dose 
Median daily 
oral dose 
Treatment group 
    
Hydroxyurea (n=152) 42.7 (1.11) 34.0 (1.10) 74.8 42.0 
Placebo (n=147) 41.3 (1.10) 34.2 (1.09) 63.6 43.3 
HU response group 
    
Responders (n=27) 54.8 (1.40) 50.5 (1.38) 112.0 193.0 
Nonresponders (n=116) 42.3 (1.12) 32.6 (1.10) 75.7 40.0 
aDerived from least squares means (LSM) estimates in mixed models of log-transformed data.  All values expressed as mg morphine equivalent. 
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Table 6 
Number and duration of acute care and in-patient painful crises 
 Number of acute 
care crises 
Number of in-
patient crises 
LOS, in-patient 
crises 
Treatment group Mean (SD),  
median 
Mean (SD),  
median 
Mean (SD),  
median 
Hydroxyurea (n=152) 6.6 (17.3), 2 6.4 (8.5), 3 7.6 (6.7), 6.0 
Placebo (n=147) 8.5 (16.7), 2 8.5 (10.1), 5 7.8 (6.5), 6.2 
HU response group 
   
Responders (n=27) 1.4 (2.9), 1 2.1 (4.1), 0 5.9 (2.6), 5.5 
Nonresponders (n=116) 7.8 (19.4), 2 7.2 (8.8), 4 7.7 (6.8), 6.0 
SD=Standard deviation, LOS=length of stay (in days). 
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Table 7. 
Cumulative equianalgesic dosing and duration: means (SDs) by response group 
 In-patient crises (n=2209) Acute care crises (n=2409) 
HU response 
group 
Cumulative 
parenteral 
dose in mg: 
mean (SD) 
Cumulative 
oral dose in 
mg: 
mean (SD)  
Cumulative 
duration in 
days: 
mean (SD) 
Cumulative 
parenteral 
dose in mg: 
mean (SD) 
Cumulative 
oral dose in 
mg: 
mean (SD)  
Cumulative 
duration in 
hours:  
mean (SD) 
Responders 
(n=27) 
1114 (2770.4) 730 (2716.3) 12.4 (24.8) 35 (96.0) 0.6 (3.1) 27 (86.9) 
Nonresponders 
(n=116) 
3848 (9187.9) 736 (2624.6) 55.3 (75.1) 391 (1447.6) 26.6 (77.6) 108 (218.7) 
Placebo  
(n=147) 
4897 (15990.1) 1155 (5303.0) 66.2 (94.4) 459 (1203.6) 68.2 (256.2) 133 (260.9) 
SD=Standard deviation, mg=mg morphine equivalent 
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Figure Legends 
 
 
 
Figure 1. Utilization of oral opioids at home 
  
Figure 2. Parenteral opioid utilization by crisis location 
 
Figure 3. Oral opioid utilization by crisis location 
 
Figure 4. Utilization of parenteral opioids in in-patient crises 
 
 
 
 
